Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
10x Genomics, Inc.
Report date July 29, 2022 · Filed August 25, 2022
Section 16 reporting ended · disclosed 2022-08-25. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2021 Filed Sep 15, 2021 18:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,694 | $175.17 | $471,899.63 |
DisclosureSEC source: 0001209191-21-056229 · doc4.xml · nonDerivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,642 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $174.73 to $175.72. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 18:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,700 | $174.14 | $470,165.58 |
DisclosureSEC source: 0001209191-21-056229 · doc4.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,336 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $173.67 to $174.65. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 18:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $172.40 | $68,958.00 |
DisclosureSEC source: 0001209191-21-056229 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,036 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $172.30 to $172.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 18:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $171.20 | $51,360.99 |
DisclosureSEC source: 0001209191-21-056229 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,436 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $170.88 to $171.66. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 18:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,300 | $170.30 | $221,394.42 |
DisclosureSEC source: 0001209191-21-056229 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,736 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $169.865 to $170.79. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 18:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,300 | $169.06 | $388,833.86 |
DisclosureSEC source: 0001209191-21-056229 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,036 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $168.75 to $169.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 18:09 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-21-056229 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 20:36 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 270 | $161.85 | $43,698.83 |
DisclosureSEC source: 0001209191-21-053390 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,336 F1 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 16:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-21-051618 · doc4.xml · derivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · derivative.exercise_date: This option, originally for 800,000 shares, of which 306,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 16:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 800 | $161.84 | $129,472.00 |
DisclosureSEC source: 0001209191-21-051618 · doc4.xml · nonDerivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,606 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $161.62 to $162.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 16:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,087 | $161.28 | $820,435.94 |
DisclosureSEC source: 0001209191-21-051618 · doc4.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,406 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $160.62 to $161.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 16:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,400 | $160.00 | $544,010.88 |
DisclosureSEC source: 0001209191-21-051618 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,493 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $159.64 to $160.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 16:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,213 | $159.13 | $511,289.51 |
DisclosureSEC source: 0001209191-21-051618 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,893 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $158.66 to $159.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 16:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,400 | $158.07 | $379,373.52 |
DisclosureSEC source: 0001209191-21-051618 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,106 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $157.66 to $158.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 16:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,100 | $157.19 | $330,099.63 |
DisclosureSEC source: 0001209191-21-051618 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,506 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $156.61 to $157.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 16:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-21-051618 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 16:42 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-21-046677 · doc4.xml · derivative · entry 9 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · derivative.exercise_date: This option, originally for 800,000 shares, of which 289,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 16:42 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $191.60 | $57,480.51 |
DisclosureSEC source: 0001209191-21-046677 · doc4.xml · nonDerivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,606 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $191.445 to $191.91. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 16:42 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $190.86 | $114,517.68 |
DisclosureSEC source: 0001209191-21-046677 · doc4.xml · nonDerivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,906 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $190.41 to $191.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 16:42 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $189.36 | $94,682.00 |
DisclosureSEC source: 0001209191-21-046677 · doc4.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,506 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $189.07 to $189.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 16:42 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,512 | $188.32 | $284,732.73 |
DisclosureSEC source: 0001209191-21-046677 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,006 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $188.015 to $188.945. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 16:42 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,933 | $187.31 | $736,674.50 |
DisclosureSEC source: 0001209191-21-046677 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,518 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $186.90 to $187.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 16:42 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,400 | $185.87 | $817,811.28 |
DisclosureSEC source: 0001209191-21-046677 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,451 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $185.47 to $186.41. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 16:42 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,755 | $185.07 | $1,065,097.42 |
DisclosureSEC source: 0001209191-21-046677 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,851 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $184.47 to $185.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 16:42 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-21-046677 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · balance_after: Includes an aggregate of 344 shares previously acquired under the Issuer's 2019 Employee Stock Purchase Plan. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 18:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-21-041034 · doc4.xml · derivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · derivative.exercise_date: This option, originally for 800,000 shares, of which 272,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 18:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $193.64 | $77,456.00 |
DisclosureSEC source: 0001209191-21-041034 · doc4.xml · nonDerivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,262 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $193.61 to $193.69. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 18:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,100 | $192.97 | $984,127.62 |
DisclosureSEC source: 0001209191-21-041034 · doc4.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,662 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $192.55 to $193.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 18:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,500 | $192.12 | $864,535.05 |
DisclosureSEC source: 0001209191-21-041034 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,762 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $191.555 to $192.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 18:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,000 | $191.16 | $573,475.50 |
DisclosureSEC source: 0001209191-21-041034 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,262 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $190.555 to $191.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 18:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,084 | $190.01 | $585,994.85 |
DisclosureSEC source: 0001209191-21-041034 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,262 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $189.49 to $190.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 18:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 916 | $189.03 | $173,147.36 |
DisclosureSEC source: 0001209191-21-041034 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,346 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $188.49 to $189.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 18:03 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-21-041034 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 24, 2021 Filed May 26, 2021 20:25 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 281 | $162.66 | $45,707.35 |
DisclosureSEC source: 0001209191-21-036100 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,262 F3 · shares: These shares were sold to cover tax withholding obligations in connection with the vesting of RSUs. F4 · balance_after: The number of shares beneficially owned following the reported transaction is as of May 24, 2021. Read SEC document |
| May 12, 2021 Filed May 13, 2021 19:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-21-032476 · doc4.xml · derivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: This option, originally for 800,000 shares, of which 255,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 12, 2021 Filed May 13, 2021 19:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 100 | $137.57 | $13,757.00 |
DisclosureSEC source: 0001209191-21-032476 · doc4.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,608 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 12, 2021 Filed May 13, 2021 19:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,200 | $136.80 | $164,163.96 |
DisclosureSEC source: 0001209191-21-032476 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,708 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $136.44 to $137.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 12, 2021 Filed May 13, 2021 19:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,702 | $135.74 | $366,781.37 |
DisclosureSEC source: 0001209191-21-032476 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,908 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $135.38 to $136.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 12, 2021 Filed May 13, 2021 19:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,875 | $134.70 | $1,060,759.35 |
DisclosureSEC source: 0001209191-21-032476 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,610 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $134.34 to $135.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 12, 2021 Filed May 13, 2021 19:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,123 | $133.86 | $685,759.14 |
DisclosureSEC source: 0001209191-21-032476 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,485 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $133.33 to $134.32. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 12, 2021 Filed May 13, 2021 19:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-21-032476 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-21-026447 · doc4.xml · derivative · entry 13 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 562,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F13 · derivative.exercise_date: This option, originally for 800,000 shares, of which 238,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $192.17 | $57,651.99 |
DisclosureSEC source: 0001209191-21-026447 · doc4.xml · nonDerivative · entry 12 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,608 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F12 · price: This transaction was executed in multiple trades at prices ranging from $192.00 to $192.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,100 | $190.31 | $209,340.45 |
DisclosureSEC source: 0001209191-21-026447 · doc4.xml · nonDerivative · entry 11 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,908 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · price: This transaction was executed in multiple trades at prices ranging from $190.01 to $191.68. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,400 | $189.34 | $265,075.30 |
DisclosureSEC source: 0001209191-21-026447 · doc4.xml · nonDerivative · entry 10 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,008 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · price: This transaction was executed in multiple trades at prices ranging from $188.98 to $189.90. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,398 | $188.36 | $451,694.71 |
DisclosureSEC source: 0001209191-21-026447 · doc4.xml · nonDerivative · entry 9 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,408 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $187.98 to $188.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,996 | $187.10 | $373,449.80 |
DisclosureSEC source: 0001209191-21-026447 · doc4.xml · nonDerivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,806 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $186.76 to $187.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,855 | $186.31 | $531,910.77 |
DisclosureSEC source: 0001209191-21-026447 · doc4.xml · nonDerivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,802 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $185.755 to $186.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,500 | $185.14 | $277,714.05 |
DisclosureSEC source: 0001209191-21-026447 · doc4.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,657 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $184.67 to $185.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 16:40 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $184.32 | $110,591.16 |
DisclosureSEC source: 0001209191-21-026447 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,157 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $183.67 to $184.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.